How should artemether/lumefantrine be dosed for uncomplicated Plasmodium falciparum malaria in adults and children, and what are the guidelines for severe cases?

Artemether-Lumefantrine Dosing and Management

For uncomplicated Plasmodium falciparum malaria in adults and children >35 kg, administer artemether-lumefantrine 4 tablets (80mg artemether/480mg lumefantrine) at 0,8,24,36,48, and 60 hours (total 24 tablets over 72 hours) with fatty food, and for severe malaria, use intravenous artesunate instead. 1

Uncomplicated Malaria Treatment

Standard Dosing Regimen

Artemether-lumefantrine (AL) is the preferred first-line artemisinin-based combination therapy (ACT) for uncomplicated P. falciparum malaria in most non-endemic countries 1. The dosing schedule is weight-based:

Adults and children >35 kg:

• 4 tablets per dose (80mg artemether/480mg lumefantrine)
• Given at: Hour 0, Hour 8, Hour 24, Hour 36, Hour 48, Hour 60
• Total: 24 tablets over 72 hours 1

Pediatric weight-based dosing (at same time intervals):

• 5 to <15 kg: 1 tablet per dose
• 15 to <25 kg: 2 tablets per dose
• 25 to <35 kg: 3 tablets per dose 2

Critical Administration Requirements

AL must be taken with fatty food or drink to ensure adequate absorption 1. This is a common pitfall—failure to take with fat significantly reduces lumefantrine exposure and increases treatment failure risk.

Emerging Resistance Concerns

Recent surveillance data reveals concerning trends. From November 2022 through October 2025, CDC documented 40 AL treatment failures, with 85% presenting as late recrudescences 1-8 weeks after initial treatment 3. The pooled treatment failure risk increased from 4% before 2018 to 7% in 2018 or later 3.

Based on these findings, CDC now recommends an extended 5-day (10-dose) course of AL for uncomplicated P. falciparum malaria in the United States, particularly for travelers returning from Africa 3. This extended regimen achieves higher lumefantrine exposure and is well tolerated 3.

Alternative First-Line Option

Dihydroartemisinin-piperaquine (320mg/40mg) is an equally preferred first-line ACT 1:

• 36-75 kg: 3 tablets daily for 3 days

• 75 kg: 4 tablets daily for 3 days

• Must be taken fasting (opposite of AL)
• Avoid in patients with QTc prolongation risk 1

Severe Malaria Treatment

Definition of Severe Malaria

Severe malaria requires parenteral therapy and includes any of the following WHO criteria 1:

• CNS: Unarousable coma, multiple convulsions
• Cardiovascular/Respiratory: Shock, pulmonary edema, ARDS
• Renal: Urine output <400mL/24 hours, creatinine >3 mg/dL
• Hematologic: Hemoglobin <7 g/dL
• Metabolic: Glucose <40 mg/dL, acidosis
• Parasitemia: >5% in non-immune patients (threshold varies 2-5% across guidelines)
• Hepatic: Jaundice with parasitemia >100,000/mL

Parenteral Treatment Protocol

Intravenous artesunate is the treatment of choice for severe malaria in all guidelines 1, 2. If artesunate is unavailable:

Quinine hydrochloride regimen:

• Loading dose: 20 mg salt/kg IV over 4 hours
• Maintenance: 10 mg/kg IV over 4 hours every 8 hours
• Continue for 7 days or until oral therapy tolerated
• Omit loading dose if patient took mefloquine in previous 24 hours or treatment dose within 3 days 2

Once able to tolerate oral medications, switch to complete treatment with full course of oral ACT (artemether-lumefantrine, dihydroartemisinin-piperaquine, or atovaquone-proguanil) 2.

Safety Profile

AL demonstrates excellent tolerability across age groups. In pooled analysis of 1,979 patients, serious adverse events occurred in only 1.4% of adults and 1.3% of children 4. Most adverse events are mild-to-moderate and malaria-related (headache, dizziness, gastrointestinal symptoms) 1, 5.

AL can be used in all trimesters of pregnancy 1, making it particularly valuable when other options are contraindicated.

Key Clinical Pitfalls

1. Fatty food requirement: AL absorption critically depends on co-administration with fat
2. Complex dosing schedule: The 6-dose regimen over 60 hours requires careful patient education
3. QTc prolongation: Monitor in at-risk patients, though clinically significant events are rare
4. Geographic resistance patterns: Consider extended 5-day regimen for African travelers given rising failure rates 3
5. Avoid oral quinine in children: Bitter taste severely affects compliance 2

Efficacy Data

Standard 3-day AL achieves PCR-corrected 28-day cure rates of 97.1% in adults and 97.3% in children 4. Median parasite clearance time is 41.5 hours with fever clearance at 36.8 hours 5. Gametocytemia after day 7 is rare (4.2% adults, 0.9% children) 4, reducing transmission potential.